Source: Annual Congress 2005 - Treatment options for moderate and severe asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Ayre, H. Fox, H. Chen, S. Hedgecock, C. Reisner (Horsham, United Kingdom; East Hanover, United States Of America). Evaluating response to omalizumab (anti-IgE) in clinical practice. Eur Respir J 2005; 26: Suppl. 49, 422

Member's Comments

No comment yet.

Related content which might interest you: Patient characteristics that can predict response to omalizumab an (anti-IgE antibody) for achieving better control of asthmatic patients Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Gender medicine and different prevalence in asthma by reports on anti-IgE (omalizumab) treatments Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 How to evaluate a patient's response to anti-IgE Source: Eur Respir Rev 2007; 16: 78-84 Year: 2007 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Free serum IgE suppression with omalizumab and clinical outcomes in asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Effectiveness of anti-IgE and anti-IL-5 treatment in step 5 asthma patients. Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Tolerability assessment of a recombinant humanized monoclonal anti-IgE antibody (omalizumab) as a treatment for seasonal allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 116s Year: 2002 The effectiveness of different clinical measures in evaluating response to omalizumab Source: Annual Congress 2010 - Questionnaires use and psychological aspects in asthma Year: 2010 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Effectiveness of different models of maintenance therapy for bronchial asthma (BA) in routine clinical practice Source: Eur Respir J 2007; 30: Suppl. 51, 70s Year: 2007 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010 Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021